Griesshammer, Martin <br/><br/>
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.  [electronic resource] 

 -  Expert opinion on pharmacotherapy  Dec 2017 
 - 1929-1938 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-7666 
<br/><br/><label>Standard No.: </label>10.1080/14656566.2017.1404574  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzamides--therapeutic use<br/>Bridged-Ring Compounds--therapeutic use<br/>Clinical Trials as Topic<br/>Fusion Proteins, bcr-abl--genetics<br/>Humans<br/>Janus Kinase Inhibitors--therapeutic use<br/>Myeloproliferative Disorders--drug therapy<br/>Nitriles<br/>Polycythemia Vera--drug therapy<br/>Primary Myelofibrosis--drug therapy<br/>Pyrazoles--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Thrombocythemia, Essential--drug therapy